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Abstract Carcinogenic activity of many polycyclic aromatic
hydrocarbons (PAHs) is mainly attributed to their respective diol
epoxides, which can be classified as either bay or fjord region
depending upon the location of the epoxide function. The Pi class
human glutathione (GSH) transferase (hGSTP1-1), which is
polymorphic in humans with respect to amino acid residues in
positions 104 (isoleucine or valine) and/or 113 (alanine or valine),
plays an important role in the detoxification of PAH-diol
epoxides. Here, we report that the location of the epoxide
function determines specificity of allelic variants of hGSTP1-1
toward racemic anti-diol epoxide isomers of benzo[c]chrysene
(B[c]C). The catalytic efficiency (kcat/Km) of V104,A113 (VA)
and V104,V113 (VV) variants of hGSTP1-1 was approximately
2.3- and 1.7-fold higher, respectively, than that of the I104,A113
(IA) isoform toward bay region isomer ( þ )-anti-B[c]C-1,2-diol-
3,4-epoxide. On the other hand, the IA variant was approxi-
mately 1.6- and 3.5-fold more efficient than VA and VV
isoforms, respectively, in catalyzing the GSH conjugation of
fjord region isomer ( þ )-anti-B[c]C-9,10-diol-11,12-epoxide. The
results of the present study clearly indicate that the location of
the epoxide function determines specificity of the allelic variants
of hGSTP1-1 in the GSH conjugation of activated diol epoxide
isomers of B[c]C. ß 2000 Federation of European Biochemical
Societies. Published by Elsevier Science B.V. All rights re-
served.
Key words: Benzo[c]chrysene; Carcinogenesis;
Glutathione transferase Pi; Polymorphism; Detoxi¢cation
1. Introduction
Many polycyclic aromatic hydrocarbons (PAHs) are human
carcinogens that are widespread in the environment. Tumori-
genic activity of PAHs is mainly due to their respective diol
epoxides, which are formed through mediation of cytochrome
P450-dependent monooxygenases and epoxide hydrolase [1].
The Pi class human glutathione (GSH) transferase (hGSTP1-
1) is believed to play an important role in the detoxi¢cation of
PAH-diol epoxides primarily by catalyzing their conjugation
with GSH [2,3]. Interestingly, the hGSTP1 gene is polymor-
phic in human populations. The allelic variants of hGSTP1-1
di¡er at amino acid residues in positions 104 (isoleucine or
valine) and/or 113 (alanine or valine) [4^6] and exhibit marked
di¡erences in their activities toward the model substrate
1-chloro-2,4-dinitrobenzene [6]. Epidemiological studies have
shown that while I104,A113 allele is the most frequent in
human populations [7^10], the frequency of the V104,A113
and (or) V104,V113 alleles is signi¢cantly higher in certain
cancers compared with the I104,A113 allele [5,7,8].
To gain insights into the toxicological relevance of
hGSTP1-1 polymorphism, we have previously examined the
speci¢cities of the allelic variants of this enzyme toward car-
cinogenic anti-diol epoxide isomers of various environmen-
tally relevant PAHs, including benzo[a]pyrene (B[a]P), chrys-
ene, 5-methylchrysene (5-MeC), benzo[g]chrysene (B[g]C), and
benzo[c]phenanthrene (B[c]P) [11^14]. Our studies show that
the V104,A113 and V104,V113 variants of hGSTP1-1 (VA
and VV, respectively) are between 1.3- and 7-fold more e⁄-
cient than the I104,A113 isoform (IA) toward (+)-anti-
benzo[a]pyrene-7,8-diol-9,10-epoxide ((+)-anti-BPDE) and
( þ )-anti-chrysene-1,2-diol-3,4-epoxide (( þ )-anti-CDE) [11,12].
Surprisingly, the above ranking of catalytic e⁄ciencies of
hGSTP1-1 variants is reversed toward certain other environ-
mentally relevant carcinogenic PAH-diol epoxides, includ-
ing (+)-anti-5-methylchrysene-1,2-diol-3,4-epoxide ((+)-anti-
5MeCDE); ( þ )-anti-benzo[g]chrysene-11,12-diol-13,14-epox-
ide (( þ )-anti-B[g]CDE), and ( þ )-anti-benzo[c]phenanthrene-
3,4-diol-1,2-epoxide (( þ )-anti-B[c]PDE), where the IA variant
is relatively more e⁄cient than VA and/or VV [13,14].
The diol epoxides implicated as the active metabolites of
PAH carcinogens generally have their epoxide function either
in a bay region or in a fjord region [1,15]. While anti-diol
epoxide isomers of the bay region class, e.g. anti-BPDE, are
planar molecules, anti-diol epoxide isomers of the fjord region
class, such as anti-B[g]CDE, have their epoxide function in a
sterically-hindered region, and their molecules are distorted
from planarity [1,15]. These results suggest that while VA
and/or VV isoforms may play a major role in the GSH con-
jugation of planar bay region PAH-diol epoxides (e.g. anti-
BPDE), the IA isoform is likely to be important in the detox-
i¢cation of non-planar and sterically-hindered fjord region
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compounds such as anti-B[g]CDE [11^14]. In the present
study we have tested the above hypothesis by determining
catalytic e⁄ciencies of the allelic variants of hGSTP1-1 to-
ward racemic anti-benzo[c]chrysene-1,2-diol-3,4-epoxide
(( þ )-anti-B[c]CDE-1) and racemic anti-benzo[c]chrysene-
9,10-diol-11,12-epoxide (( þ )-anti-B[c]CDE-2), which are the
activated forms of benzo[c]chrysene (B[c]C) [16]. B[c]C is in-
triguing due to the presence of both, a bay region and a fjord
region in the same molecule. As shown in Fig. 1, the epoxide
function in the ( þ )-anti-B[c]CDE-1 isomer is in a bay region,
whereas ( þ )-anti-B[c]CDE-2 has fjord region characteristics
due to the location of its epoxide function in a sterically-hin-
dered region. In this communication we report that the loca-
tion of the epoxide function determines catalytic e⁄ciency of
the allelic variants of hGSTP1-1 toward ( þ )-anti-B[c]CDE
isomers.
2. Materials and methods
2.1. Expression and puri¢cation of allelic variants of hGSTP1-1
The hGSTP1-1 variants were expressed and puri¢ed by GSH a⁄n-
ity chromatography as described previously [11].
2.2. Determination of GST activity toward ( þ )-anti-B[c]CDE isomers
The ( þ )-anti-B[c]CDE isomers were synthesized and puri¢ed as
described previously [17]. The reaction mixture in a ¢nal volume of
0.1 ml consisted of Tris/HCl bu¡er (pH 7.5) containing 2.5 mM KCl
and 0.5 mM EDTA (TKE bu¡er), 2 mM GSH, and desired concen-
trations of ( þ )-anti-B[c]CDE-1 or ( þ )-anti-B[c]CDE-2 and hGSTP1-
1 isoform protein. The reaction was initiated by adding the diol ep-
oxide substrate, and the reaction mixture was incubated for 30 s at
37‡C. The reaction was stopped by rapidly adding 0.1 ml of chilled
acetone, and the unreacted ( þ )-anti-B[c]CDE was removed by ex-
tracting the reaction mixture with ethyl acetate saturated with TKE
bu¡er. The GSH conjugate of ( þ )-anti-B[c]CDE-1 or ( þ )-anti-
B[c]CDE-2 in the aqueous phase was quanti¢ed by reverse-phase
HPLC using a Waters Nova-Pak C18 (3.9U150 mm) column. This
column was preequilibrated with 80% solvent I (5% acetonitrile in
0.1% tri£uoroacetic acid) and 20% solvent II (90% acetonitrile in
0.1% tri£uoroacetic acid). The GSH conjugates of anti-B[c]CDE-1
and anti-B[c]CDE-2 were eluted with a 20^30% linear gradient of
solvent II in 20 min at a £ow rate of 1 ml min31. Under these con-
ditions, the GSH conjugates of anti-B[c]CDE-1 and anti-B[c]CDE-2
were eluted at retention times of about 12 and 7.5 min, respectively.
Initially, the GST activity was measured as a function of varying
hGSTP1-1 protein concentration to optimize the assay conditions.
In subsequent studies, 60 and 120 Wg ml31 of hGSTP1-1 isoform
protein were used for incubations involving anti-B[c]CDE-1 and
anti-B[c]CDE-2, respectively. For ( þ )-anti-B[c]CDE-1, the GST activ-
ity was measured as a function of varying diol epoxide concentration
(10^320 WM) at a ¢xed saturating concentration of GSH (2 mM) to
determine the kinetic parameters. The Km, Vmax, and kcat/Km (cata-
lytic e⁄ciency) values were determined by non-linear regression anal-
ysis of the experimental data points. The catalytic e⁄ciencies of
hGSTP1-1 variants toward ( þ )-anti-B[c]CDE-2 were calculated
from initial rate measurements at low (10 WM) substrate concentra-
tions, as described in [18], because saturation curves could not be
obtained for this isomer.
3. Results and discussion
Fig. 2A exempli¢es a reverse-phase HPLC elution pro¢le of
Fig. 1. Structures of benzo[c]chrysene and its bay region (( þ )-anti-
B[c]CDE-1) and fjord region (( þ )-anti-B[c]CDE-2) diol epoxide iso-
mers.
Fig. 2. Reverse-phase HPLC analysis of water-soluble products re-
sulting from the reaction of 2 mM GSH with (A) 10 WM ( þ )-anti-
B[c]CDE-1, and (B) 10 WM ( þ )-anti-B[c]CDE-2 in the presence of
hGSTP1-1 protein. The concentrations of hGSTP1-1 variants were
60 Wg ml31 and 120 Wg ml31 for ( þ )-anti-B[c]CDE-1 and ( þ )-anti-
B[c]CDE-2, respectively.
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water-soluble products resulting from the reaction of 2 mM
GSH and 10 WM ( þ )-anti-B[c]CDE-1 for 30 s in the presence
of allelic variants of hGSTP1-1. Non-enzymatic (spontaneous)
conjugation of ( þ )-anti-B[c]CDE-1 with GSH was not detect-
able (data not shown in Fig. 2A). The levels of GSH conju-
gate of anti-B[c]CDE-1 in the reaction mixtures containing
hGSTP1-1 variants VA and VV exceeded those observed
with IA by about 2.8- and 1.6-fold, respectively. Interestingly,
as shown in Fig. 2B, the IA variant, not VA or VV, was found
to be most e¡ective in catalyzing the GSH conjugation of
( þ )-anti-B[c]CDE-2. Non-enzymatic GSH conjugation of
( þ )-anti-BCCDE-2 was also not detectable (data not shown
in Fig. 2B).
All three variants of hGSTP1-1 adhered to Michaelis^
Menten kinetics toward ( þ )-anti-B[c]CDE-1 (data not shown).
Table 1 summarizes the kinetic constants for hGSTP1-1 var-
iants toward ( þ )-anti-B[c]CDE-1. The Vmax values for the VA
and VV isoforms did not di¡er from each other, but both
were signi¢cantly higher (approximately 6.7-fold) than that
for the IA variant. While the Km for the VV isoform was
signi¢cantly higher (approximately 4.0-fold) than for the IA
isoform, this parameter did not di¡er signi¢cantly between
either IA and VA or VA and VV variants. Of the three var-
iants, VA was found to be most e⁄cient in catalyzing the
GSH conjugation of ( þ )-anti-B[c]CDE-1. While VA was ap-
proximately 2.3-fold more e⁄cient catalytically than IA
(PW0.05), the catalytic e⁄ciencies of VA and VV were not
signi¢cantly di¡erent from each other. Even though the VV
isoform was about 1.7-fold more e⁄cient than IA in catalyz-
ing the GSH conjugation of ( þ )-anti-B[c]CDE-1, this di¡er-
ence did not reach statistical signi¢cance.
Unlike ( þ )-anti-B[c]CDE-1, concentrations of ( þ )-anti-
B[c]CDE-2 approaching saturation of the enzyme could not
be attained (data not shown). Therefore, catalytic e⁄ciencies
toward ( þ )-anti-B[c]CDE-2 were calculated from the initial
reaction rate measurements at 10 WM substrate concentration,
as described by us previously [14]. As shown in Fig. 3, the IA
variant of hGSTP1-1 was found to be most e⁄cient in cata-
lyzing the GSH conjugation of the ( þ )-anti-B[c]CDE-2 iso-
mer. The catalytic e⁄ciency of the IA isoform was signi¢-
cantly higher (P = 0.001) than that of either VA (about 1.6-
fold) or VV (about 3.5-fold). The catalytic e⁄ciencies of VA
and VV toward ( þ )-anti-B[c]CDE-2 were also statistically sig-
ni¢cantly di¡erent from each other at P = 0.001.
We were the ¢rst to report that allelic variants of hGSTP1-1
signi¢cantly di¡er in their ability to catalyze the GSH conju-
gation (detoxi¢cation) of the ultimate carcinogenic metabo-
lites (diol epoxides) of certain PAHs [11^14]. We found that
hGSTP1-1 variants with valine in position 104 (VA and VV)
are relatively more e⁄cient than the IA isoform toward (+)-
anti-BPDE [11,12], which is a planar PAH-diol epoxide. Our
observations on di¡erences in catalytic e⁄ciencies between
hGSTP1-1 variants toward (+)-anti-BPDE have been inde-
pendently con¢rmed by other investigators [19]. Subsequently,
we showed that the hGSTP1-1 variants with valine in position
104 are signi¢cantly more e⁄cient than the IA isoform in
catalyzing the GSH conjugation of ( þ )-anti-CDE [11,12],
which, like (+)-anti-BPDE, is a planar molecule. Surprisingly,
the IA isoform, not VA or VV, was found to be most e¡ective
toward ( þ )-anti-B[g]CDE and ( þ )-anti-B[c]PDE [14]. One
common feature among these diol epoxides is that their epox-
ide group is in a sterically-hindered region, and these mole-
cules are distorted from planarity. Based on these observa-
tions, we predicted that while VA and/or VV isoforms may
play a major role in the detoxi¢cation of bay region diol
epoxides, the IA variant is likely to be important in the
GSH conjugation of fjord region PAH-diol epoxides.
B[c]C, a constituent of coal tar and crude oil, presented us
with a unique opportunity to test the above hypothesis since
this environmental pollutant can be activated to both a bay
region as well as a fjord region diol epoxide (Fig. 1). The
results of the present study clearly demonstrate that the VA
and VV isoforms are more e⁄cient than IA toward ( þ )-anti-
B[c]CDE-1, which is a bay region class diol epoxide. On the
other hand, the IA isoform is signi¢cantly more e⁄cient than
either VA or VV toward the ( þ )-anti-B[c]CDE-2 isomer,
which has fjord region characteristics due to the location of
its epoxide function in a sterically-hindered region.
Sundberg et al. [20] have also compared the e⁄ciencies of
the IA and VA variants of hGSTP1-1 in catalyzing the GSH
Table 1
Kinetic constants for hGSTP1-1 variants toward ( þ )-anti-B[c]CDE-1
Kinetic constants hGSTP1-1 variant
IA VA VV
Vmax (nmol mg31 min31) 16 þ 2a;b 107 þ 21 107 þ 20
Km (WM) 111 þ 27b 314 þ 106 446 þ 126
kcat (s31) 0.014a;b 0.089 0.088
kcat/Km (mM31 s31) 0.12 þ 0.02a 0.28 þ 0.04 0.20 þ 0.02
Values are means þ S.E.M. of three determinations. The kinetic parameters for VA and VV do not di¡er signi¢cantly from each other.
aStatistically signi¢cantly di¡erent from VA.
bStatistically signi¢cantly di¡erent from VV.
Fig. 3. Catalytic e⁄ciencies of hGSTP1-1 variants toward ( þ )-anti-
B[c]CDE-2. Data are means þ S.E.M. of three determinations. The
catalytic e⁄ciency values were calculated from initial reaction rates
at 10 WM substrate concentration. One-way ANOVA followed by
multiple comparisons with appropriate corrections (Duncan, Sche¡e)
reveals that the catalytic e⁄ciency of every isoenzyme is di¡erent
from the other two at P = 0.001.
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conjugation of certain fjord region class PAH-diol epoxides,
including optically pure (3)-enantiomers of anti-B[c]CDE-2
and anti-B[g]CDE. While VV variant was not examined, the
catalytic e⁄ciencies of the IA and VA isoforms of hGSTP1-1
toward (3)-anti-B[g]CDE were found to be comparable [20].
Previous studies from our laboratory using racemic anti-
B[g]CDE have also shown that the catalytic e⁄ciency of the
IA variant (0.36 mM31 s31) is not statistically signi¢cantly
di¡erent from that of VA (0.31 mM31 s31) [14]. On the other
hand, our results are di¡erent from those of Sundberg et al.
[20] with respect to activity of hGSTP1-1 isoforms toward
anti-B[c]CDE-2. The results of the present study reveal that
the IA isoform is signi¢cantly more e⁄cient than VA in cata-
lyzing the GSH conjugation of anti-B[c]CDE-2. Unlike our
observations, IA and VA were found to be equally e¡ective
toward optically pure (3)-anti-B[c]CDE-2 by Sundberg et al.
[20]. In addition, the catalytic e⁄ciency values for hGSTP1-1
variants obtained during the present investigation using race-
mic anti-B[c]PDE-2 are relatively lower than those reported by
Sundberg et al. [20]. While reasons for these discrepancies are
not known, some possibilities exist that may explain these
di¡erences. First, it is possible that the (+)-enantiomer of
anti-B[c]CDE-2 acts as an inhibitor of hGSTP1-1 catalyzed
GSH conjugation of the (3)-anti-B[c]CDE-2 isomer if incuba-
tions are performed using racemic substrate, which was the
case in the present study. In this regard, it is important to
point out that the (3)-anti-BPDE isomer has been shown to
inhibit GSH conjugation of (+)-anti-BPDE [2]. Second, the
catalytic e⁄ciencies toward racemic anti-B[c]CDE-2 in the
present study are calculated from initial reaction rate mea-
surements at 10 WM substrate concentration since concentra-
tions of ( þ )-anti-B[c]CDE-2 approaching saturation of the
enzyme could not be attained. On the other hand, Sundberg
et al. [20] used concentrations of 40 and 80 WM to determine
catalytic e⁄ciencies of hGSTP1-1 variants toward (3)-anti-
B[c]CDE-2. Despite these discrepancies, however, the results
of the present study taken together with our earlier ¢ndings
clearly demonstrate di¡erences in speci¢cities of allelic var-
iants of hGSTP1-1 toward bay- and fjord region class diol
epoxides of various environmentally relevant PAH carcino-
gens [11^14].
In conclusion, the results of the present work, taken togeth-
er with our previous studies [11^14], indicate that the catalytic
e⁄ciency of allelic variants of hGSTP1-1 toward PAH-diol
epoxides is dependent upon the location (fjord versus bay
region) of the epoxide group in these environmental carcino-
gens. Our results suggest that the putative role of hGSTP1-1
polymorphism in humans with regard to the susceptibility of
individuals to PAH-induced carcinogenesis may be more com-
plex than currently realized.
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